Nintedanib Teva

Nintedanib, the active ingredient in Nintedanib Teva, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and non‑small cell lung cancer in adult patients where disease‑modifying therapy is required.

GNH USA supplies Nintedanib Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for global distribution.

Nintedanib is used in fibrotic lung disorders and certain oncologic settings, targeting disease pathways that drive fibrosis and tumor growth.

Idiopathic pulmonary fibrosis: slows disease progression and reduces decline in lung function. Systemic sclerosis‑associated interstitial lung disease: helps preserve lung capacity and delay worsening. Non‑small cell lung cancer: used in combination therapy to inhibit tumor growth.

Nintedanib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Diarrhea - Abdominal pain - Decreased appetite - Elevated liver enzymes (ALT/AST) - Headache

Serious or Rare Side Effects: - Severe liver injury (hepatotoxicity) - Arterial thromboembolic events (e.g., myocardial infarction, stroke) - Major bleeding episodes

Before initiating therapy, clinicians should assess baseline organ function and risk factors.

Monitor liver function: obtain baseline and periodic hepatic enzyme tests. Assess cardiovascular risk: evaluate for history of arterial thromboembolism. Avoid concomitant strong CYP3A4 inhibitors: may increase nintedanib exposure. Use caution in patients with renal impairment: adjust monitoring. Store at ambient temperature: keep in the original pack, protect from moisture and light.

Nintedanib can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise nintedanib levels. - Anticoagulants (e.g., warfarin): increased bleeding risk. - P‑glycoprotein inhibitors (e.g., verapamil): may increase exposure.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inducers (e.g., rifampin): may reduce efficacy. - Antiplatelet agents (e.g., aspirin): monitor for bleeding. - Diuretics: watch for dehydration and renal function changes.